NOS2 and breast carcinoma: Based on cBioportal analysis, we found that the overall survival time of breast cancer patients with one gene mutation in PRKDC, NOS2, ARG1, or IDO1 was significantly shorter compared with patients without the mutations (Figure 2A–D).